Classification and recommended treatment options for folliculotropic mycosis fungoides

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15;105(10):3768–3785. PubMed PMID: 15692063. DOI:10.1182/blood-2004-09-3502
   PubMed Web of Science ®Google Scholar
• Van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002 Feb;138(2):191–198. PubMed PMID: 11843638.
   PubMedGoogle Scholar
• Gerami P, Rosen S, Kuzel T, et al. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008 Jun;144(6):738–746. PubMed PMID: 18559762. DOI:10.1001/archderm.144.6.738
   PubMedGoogle Scholar
• Lehman JS, Cook-Norris RH, Weed BR, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010 Jun;146(6):607–613. PubMed PMID: 20566923. DOI:10.1001/archdermatol.2010.101
   PubMedGoogle Scholar
• Giovannini S. Über einen Fall universeller Alopecia areata in Verbindung mit Mycosis fungoides [On a case of alopecia areata universalis associated with mycosis fungoides]. Arch Derm Syphilol. 1906;78:3–20.
   Google Scholar
• Pinkus H. Alopecia mucinosa; inflammatory plaques with alopecia characterized by root-sheath mucinosis. AMA Arch Dermatol. 1957 Oct;76(4):419–424. discussion 424–6. PubMed PMID: 13457423.
   PubMedGoogle Scholar
• Jablonska S, Chorzelski T, Lancucki J. [Mucinosis follicularis]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 1959 Jan;10:27–33. PubMed PMID: 14406240.
   Google Scholar
• Braun-Falco O. Mucophanerosis intrafollicularis et seboglandularis. Dermatol Wochenschr. 1957;136(48):1289–1303.
   Google Scholar
• Cerroni L. Pilotropic mycosis fungoides: a clinicopathologic variant of mycosis fungoides yet to be completely understood. Arch Dermatol. 2010 Jun;146(6):662–664. PubMed PMID: 20566930; eng. DOI:10.1001/archdermatol.2010.93
   PubMedGoogle Scholar
• Vergier B, Beylot-Barry M, Beylot C, et al. Pilotropic cutaneous T-cell lymphoma without mucinosis. A variant of mycosis fungoides? French Study Group of cutaneous lymphomas. Arch Dermatol. 1996 Jun;132(6):683–687. PubMed PMID: 8651719.
   PubMedGoogle Scholar
• Van Santen S, Roach RE, Van Doorn R, et al. Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol. 2016 Sep 01;152(9):992–1000. PubMed PMID: 27276223. DOI:10.1001/jamadermatol.2016.1597
   PubMed Web of Science ®Google Scholar
• Hodak E, Amitay-Laish I, Atzmony L, et al. New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol. 2016 Aug;75(2):347–355. PubMed PMID: 27245278. DOI:10.1016/j.jaad.2016.03.009
   PubMed Web of Science ®Google Scholar
• van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000 Apr;136(4):504–510. PubMed PMID: 10768649.
   PubMedGoogle Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol: J Am Soc Clin Oncol. 2010 Nov 1;28(31):4730–4739. PubMed PMID: 20855822. DOI:10.1200/JCO.2009.27.7665
   PubMed Web of Science ®Google Scholar
• Wieser I, Wang C, Alberti-Violetti S, et al. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res. 2017 Aug;309(6):453–459. PubMed PMID: 28516243. DOI:10.1007/s00403-017-1744-1
   PubMed Web of Science ®Google Scholar
• Hodak E, Amitay-Laish I, Feinmesser M, et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol. 2014 Jun;70(6):993–1001. PubMed PMID: 24629999. DOI:10.1016/j.jaad.2013.12.029
   PubMed Web of Science ®Google Scholar
• Klemke CD, Dippel E, Assaf C, et al. Follicular mycosis fungoides. Br J Dermatol. 1999 Jul;141(1):137–140. PubMed PMID: 10417530.
   PubMed Web of Science ®Google Scholar
• Marschalko M, Eros N, Kontar O, et al. Folliculotropic mycosis fungoides: clinicopathological analysis of 17 patients. J Eur Acad Dermatol Venereol: JEADV. 2015 May;29(5):964–972. PubMed PMID: 25406034. DOI:10.1111/jdv.12743
   PubMed Web of Science ®Google Scholar
• Deonizio JM, Ascef RD, Sanches JA. Folliculotropic mycosis fungoides: clinical and epidemiological evaluation in a single center in Brazil. Int J Dermatol. 2016 May;55(5):e256–61. PubMed PMID: 26711732. DOI:10.1111/ijd.13149
   PubMed Web of Science ®Google Scholar
• Demirkesen C, Esirgen G, Engin B, et al. The clinical features and histopathologic patterns of folliculotropic mycosis fungoides in a series of 38 cases. J Cutan Pathol. 2015 Jan;42(1):22–31. PubMed PMID: 25376535. DOI:10.1111/cup.12423
   PubMed Web of Science ®Google Scholar
• Mantaka P, Helsing P, Gjersvik P, et al. Clinical and histopathological features of folliculotropic mycosis fungoides: a Norwegian patient series. Acta Derm Venereol. 2013 May;93(3):325–329. PubMed PMID: 23053197. DOI:10.2340/00015555-1476
   PubMed Web of Science ®Google Scholar
• Muniesa C, Estrach T, Pujol RM, et al. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol. 2010 Mar;62(3):418–426. PubMed PMID: 20079954. DOI:10.1016/j.jaad.2009.03.014
   PubMed Web of Science ®Google Scholar
• Tomasini C, Kempf W, Novelli M, et al. Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases. J Cutan Pathol. 2015 Mar;42(3):164–172. PubMed PMID: 25355400. DOI:10.1111/cup.12399
   PubMed Web of Science ®Google Scholar
• Gerami P, Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007 Sep;31(9):1430–1438. PubMed PMID: 17721200. DOI:10.1097/PAS.0b013e3180439bdc
   PubMed Web of Science ®Google Scholar
• Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood. 2000 Apr 01;95(7):2212–2218. PubMed PMID: 10733487; eng.
   PubMed Web of Science ®Google Scholar
• Barberio E, Thomas L, Skowron F, et al. Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol. 2007 Aug;157(2):284–289. PubMed PMID: 17573879; eng. DOI:10.1111/j.1365-2133.2007.08008.x
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep 15;110(6):1713–1722. PubMed PMID: 17540844. DOI:10.1182/blood-2007-03-055749
   PubMed Web of Science ®Google Scholar
• Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013 Sep;49(13):2859–2868. PubMed PMID: 23735705. DOI:10.1016/j.ejca.2013.04.018
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - update 2017. Eur J Cancer. 2017 May;77:57–74. PubMed PMID: 28365528. DOI:10.1016/j.ejca.2017.02.027
   PubMed Web of Science ®Google Scholar
• Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: J Eur Soc Med Oncol/ESMO. 2013 Oct;24(Suppl 6):vi149–54. PubMed PMID: 23868906; eng. DOI:10.1093/annonc/mdt242
   PubMed Web of Science ®Google Scholar
• Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16(4): 283–287. PubMed PMID: 14686970.
   PubMedGoogle Scholar
• van Santen S, Van Doorn R, Neelis KJ, et al. Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2017 Jul;177(1):223–228. PubMed PMID: 28132406. DOI:10.1111/bjd.15355
   PubMed Web of Science ®Google Scholar
• Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4): 288–298. PubMed PMID: 14686971.
   PubMedGoogle Scholar
• Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25–32. PubMed PMID: 23069814; PubMed Central PMCID: PMCPMC3662469. eng. DOI:10.1001/2013.jamadermatol.541
   PubMed Web of Science ®Google Scholar
• Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002 Mar;138(3):325–332. PubMed PMID: 11902983.
   PubMed Web of Science ®Google Scholar
• Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003 Nov;49(5):801–815. PubMed PMID: 14576658. DOI:10.1067/S0190
   PubMed Web of Science ®Google Scholar
• Walling HW, Swick BL, Gerami P, et al. Folliculotropic mycosis fungoides responding to bexarotene gel. J Drugs Dermatol: JDD. 2008 Feb;7(2):169–171. PubMed PMID: 18335654.
   PubMed Web of Science ®Google Scholar
• Baykal C, Atci T, Sari SO, et al. Underrecognized clinical features of folliculotropic mycosis fungoides: a large clinical series. J Der Deutschen Dermatologischen Gesellschaft = Jl German Soc Dermatol: JDDG. 2017 Feb 27;15:289–299. PubMed PMID: 28240409; eng. DOI:10.1111/ddg.12976
   Web of Science ®Google Scholar
• Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016 Jan;74(1):27–58. PubMed PMID: 26547257. DOI:10.1016/j.jaad.2015.09.033
   PubMed Web of Science ®Google Scholar
• Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol. 1998 Dec;134(12):1582–1585. PubMed PMID: 9875197; eng.
   PubMedGoogle Scholar
• Pavlotsky F, Hodak E, Ben Amitay D, et al. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides. J Am Acad Dermatol. 2014 Sep;71(3):536–541. PubMed PMID: 24836546. DOI:10.1016/j.jaad.2014.04.011
   PubMed Web of Science ®Google Scholar
• Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop report. Br J Dermatol. 2004 Aug;151(2):283–297. PubMed PMID: 15327535; eng. DOI:10.1111/j.1365-2133.2004.06128.x
   PubMed Web of Science ®Google Scholar
• Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):154–158. PubMed PMID: 18834672. DOI:10.1016/j.ijrobp.2008.06.1918
   PubMed Web of Science ®Google Scholar
• Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):32–39. PubMed PMID: 25863751. DOI:10.1016/j.ijrobp.2015.01.008
   PubMed Web of Science ®Google Scholar
• Thomas TO, Agrawal P, Guitart J, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013 Mar 01;85(3):747–753. PubMed PMID: 22818412; eng. DOI:10.1016/j.ijrobp.2012.05.034
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, Feinmesser M, Ben-Amitai D, et al. Unilesional folliculotropic mycosis fungoides: a unique variant of cutaneous lymphoma. J Eur Acad Dermatol Venereol: JEADV. 2016 Jan;30(1):25–29. PubMed PMID: 25405551. DOI:10.1111/jdv.12851
   PubMed Web of Science ®Google Scholar
• Kempf W, Kazakov DV, Schermesser M, et al. Unilesional follicular mycosis fungoides: report of two cases with progression to tumor stage and review of the literature. J Cutan Pathol. 2012 Sep;39(9):853–860. PubMed PMID: 22882174. DOI:10.1111/j.1600-0560.2012.01965.x
   PubMed Web of Science ®Google Scholar
• van Santen S MPMJ, MD PhD, Vermeer MH MD PhD, Willemze R MD PhD. Folliculotropic mycosis fungoides presenting with a solitary lesion: clinicopathological features and long-term follow-up data in a series of nine cases. J Cutan Pathol 2017. [Epub ahead of print].
   PubMedGoogle Scholar
• Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015 Feb;72(2):286–292. PubMed PMID: 25476993. DOI:10.1016/j.jaad.2014.10.014
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Gniadecki R, Iversen L, et al. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):138–143. PubMed PMID: 25863761. DOI:10.1016/j.ijrobp.2015.01.047
   PubMed Web of Science ®Google Scholar
• Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005 Apr;115(4):798–812. PubMed PMID: 15841167; PubMed Central PMCID: PMC1070436. DOI:10.1172/JCI24826
   PubMed Web of Science ®Google Scholar
• Huen AO, Kim EJ. The role of systemic retinoids in the treatment of cutaneous T-Cell lymphoma. Dermatol Clin. 2015 Oct;33(4):715–729. PubMed PMID: 26433844; eng. DOI:10.1016/j.det.2015.05.007
   PubMed Web of Science ®Google Scholar
• Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987 Feb;123(2):201–204. PubMed PMID: 2949706; eng.
   PubMed Web of Science ®Google Scholar
• Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol. 2009 Jun;160(6):1299–1307. PubMed PMID: 19222457. DOI:10.1111/j.1365-2133.2009.09037.x
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol: J Am Soc Clin Oncol. 2001 May 01;19(9):2456–2471. PubMed PMID: 11331325; eng. DOI:10.1200/jco.2001.19.9.2456
   PubMed Web of Science ®Google Scholar
• Wieser I, Wang C, Alberti-Violetti S, et al. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res. 2017 May 17 PubMed PMID: 28516243. DOI:10.1007/s00403-017-1744-1
   PubMed Web of Science ®Google Scholar
• Drugeon C, Charlat I, Boulinguez S, et al. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma]. Ann Dermatol Venereol. 2007 Aug-Sep;134(8–9):639–643. PubMed PMID: 17925686; fre.
   PubMed Web of Science ®Google Scholar
• Shistik G, Scalf LA, Fenske N, et al. Follicular mycosis fungoides: successful treatment with oral bexarotene. J Drugs Dermatol: JDD. 2004 May-Jun;3(3):301–304. PubMed PMID: 15176165.
   PubMedGoogle Scholar
• Leverkus M, Rose C, Brocker EB, et al. Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol. 2005 Jan;152(1):193–194. PubMed PMID: 15656836. DOI:10.1111/j.1365-2133.2005.06360.x
   PubMed Web of Science ®Google Scholar
• Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4): 311–321. PubMed PMID: 14686974.
   PubMedGoogle Scholar
• Baratli J, Balakirski G, Megahed M. [Folliculotropic mycosis fungoides]. Hautarzt. 2014 Dec;65(12):1011–1013. PubMed PMID: 25355498; ger. DOI:10.1007/s00105-014-3539-z
   PubMed Web of Science ®Google Scholar
• Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 01;109(9):1799–1803. PubMed PMID: 17366595; eng. DOI:10.1002/cncr.22596
   PubMed Web of Science ®Google Scholar
• Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon −2a plus acitretin versus interferon −2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998 Nov 15;92(10):3578–3581. PubMed PMID: 9808550; eng.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 01;109(1):31–39. PubMed PMID: 16960145; PubMed Central PMCID: PMCPMC1785068. eng. DOI:10.1182/blood-2006-06-025999
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol: J Am Soc Clin Oncol. 2007 Jul 20;25(21):3109–3115. PubMed PMID: 17577020; eng. DOI:10.1200/jco.2006.10.2434
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol: J Am Soc Clin Oncol. 2010 Oct 10;28(29):4485–4491. PubMed PMID: 20697094. DOI:10.1200/JCO.2010.28.9066
   PubMed Web of Science ®Google Scholar
• Foss F, Duvic M, Lerner A, et al. Clinical efficacy of romidepsin in tumor stage and folliculotropic mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):637–643. PubMed PMID: 27637428; eng. DOI:10.1016/j.clml.2016.08.009
   PubMed Web of Science ®Google Scholar
• Kim YH, Demierre MF, Kim EJ, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma. 2013 Feb;54(2):284–289. PubMed PMID: 22839723. DOI:10.3109/10428194.2012.711829
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458–1465. PubMed PMID: 12714494; eng. DOI:10.1182/blood-2003-01-0039
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol: J Am Soc Clin Oncol. 2012 Jun 20;30(18):2190–2196. PubMed PMID: 22614995. DOI:10.1200/JCO.2011.38.0402
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol: J Am Soc Clin Oncol. 2015 Nov 10;33(32):3750–3758. PubMed PMID: 26195720; PubMed Central PMCID: PMCPMC5089160 online at www.jco.org. Author contributions are found at the end of this article. eng. DOI:10.1200/jco.2014.60.3969
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-Cell lymphoma and lymphomatoid papulosis. J Clin Oncol: J Am Soc Clin Oncol. 2015 Nov 10;33(32):3759–3765. PubMed PMID: 26261247; PubMed Central PMCID: PMCPMC4737859. eng. DOI:10.1200/jco.2014.60.3787
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 05;390(10094):555–566. PubMed PMID: 28600132; eng. DOI:10.1016/s0140-6736(17)31266-7
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr., Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994 Oct 15;121(8):592–602. PubMed PMID: 8085692; eng.
   PubMed Web of Science ®Google Scholar
• Chung CG, Poligone B. Other chemotherapeutic agents in cutaneous T-Cell lymphoma. Dermatol Clin. 2015 Oct;33(4):787–805. PubMed PMID: 26433850; eng. DOI:10.1016/j.det.2015.05.012
   PubMed Web of Science ®Google Scholar
• Molin L, Thomsen K, Volden G, et al. Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol. 1980;60(6):542–544. PubMed PMID: 6162347.
   PubMed Web of Science ®Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood. 2009 Nov 12;114(20):4337–4353. PubMed PMID: 19696197. DOI:10.1182/blood-2009-07-202895
   PubMed Web of Science ®Google Scholar
• Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015 Jan 01;125(1):71–81. PubMed PMID: 25336628. DOI:10.1182/blood-2014-07-588236
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol: J Am Soc Clin Oncol. 2000 Jul;18(13):2603–2606. PubMed PMID: 10893292. DOI:10.1200/JCO.2000.18.13.2603
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Stefoni V, Casadei B, et al. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol. 2014 Nov;93(11):1853–1857. PubMed PMID: 24908331. DOI:10.1007/s00277-014-2121-1
   PubMed Web of Science ®Google Scholar
• Illidge T, Chan C, Counsell N, et al. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer. 2013 Nov 12;109(10):2566–2573. PubMed PMID: 24136145; PubMed Central PMCID: PMCPMC3833210. eng. DOI:10.1038/bjc.2013.616
   PubMed Web of Science ®Google Scholar
• Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome. Arch Dermatol. 2008 Jun;144(6):727–733. PubMed PMID: 18559761; eng. DOI:10.1001/archderm.144.6.727
   PubMedGoogle Scholar
• di Lorenzo G, di Trolio R, Delfino M, et al. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol. 2005 Jul;153(1):183–185. PubMed PMID: 16029347. DOI:10.1111/j.1365-2133.2005.06682.x
   PubMed Web of Science ®Google Scholar
• Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica. 2007 May;92(5):686–689. PubMed PMID: 17488695.
   PubMed Web of Science ®Google Scholar
• Virmani P, Zain J, Rosen ST, et al. Hematopoietic stem cell transplant for mycosis fungoides and sezary syndrome. Dermatol Clin. 2015 Oct;33(4):807–818. PubMed PMID: 26433851; eng. DOI:10.1016/j.det.2015.05.014
   PubMed Web of Science ®Google Scholar
• Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol: J Am Soc Clin Oncol. 2010 May 10;28(14):2365–2372. PubMed PMID: 20351328; eng. DOI:10.1200/jco.2009.25.8301
   PubMed Web of Science ®Google Scholar
• Schneeweiss M, Porpaczy E, Koch M, et al. Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. Leuk Lymphoma. 2016;57(1):206–208. PubMed PMID: 25907615; eng. DOI:10.3109/10428194.2015.1044748
   PubMed Web of Science ®Google Scholar
• Mehra T, Ikenberg K, Moos RM, et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA Dermatol. 2015 Jan;151(1):73–77. PubMed PMID: 25317818; eng. DOI:10.1001/jamadermatol.2014.1629
   PubMed Web of Science ®Google Scholar
• Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol: J Eur Soc Med Oncol/ESMO. 2015 Dec;26(12):2490–2495. PubMed PMID: 26416896; PubMed Central PMCID: PMC4855245. DOI:10.1093/annonc/mdv473
   PubMed Web of Science ®Google Scholar
• Duarte RF, Boumendil A, Onida F, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party extended analysis. J Clin Oncol: J Am Soc Clin Oncol. 2014 Oct 10;32(29):3347–3348. PubMed PMID: 25154828. DOI:10.1200/JCO.2014.57.5597
   PubMed Web of Science ®Google Scholar